Our attorneys are investigating lawsuits for California residents diagnosed with T-cell lymphoma after using Dupixent (dupilumab) injections. Recent scientific studies and FDA safety investigations have identified concerning links between this widely prescribed medication and rare but aggressive forms of cancer.
What is Dupixent?
Dupixent is an injectable biologic medication manufactured by Sanofi-Aventis and Regeneron. It was approved in 2017 to treat moderate-to-severe eczema (atopic dermatitis) and is now used for asthma and chronic sinus issues.
Dupixent works by blocking specific proteins in the immune system to stop inflammation. While this helps relieve symptoms, it may also come with a dangerous cost. By suppressing the immune system, the drug may disrupt the body’s ability to detect or control cancer cells, potentially allowing malignancies to spread unchecked.
T-Cell Lymphoma Risks
The lawsuits involve T-cell lymphomas, rare cancers that start in the body’s white blood cells. The primary cancers linked to Dupixent include Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).
Cutaneous T-cell Lymphoma is the most common type associated with Dupixent. It causes cancerous cells to attack the skin. The two main subtypes are Mycosis Fungoides and the more aggressive Sézary Syndrome. Peripheral T-cell Lymphoma refers to a group of internal cancers that can affect the lymph nodes, blood, and other organs.
A major danger with these cancers is that their early symptoms look exactly like eczema. Patients experience red, scaly, itchy skin that is nearly identical to the condition Dupixent is prescribed to treat. Dupixent can reduce the itching and redness, effectively masking the cancer. This creates a false sense of security, leading to years of misdiagnosis while the cancer quietly advances to a terminal stage.
Scientific Evidence and FDA Investigation
Peer-reviewed medical studies from 2024 and 2025 have found statistically significant links between Dupixent and lymphoma. A 2024 study in the Journal of the American Academy of Dermatology (JAAD) found that eczema patients treated with Dupixent had a risk of developing CTCL that was over four times higher than those not on the drug.
A 2025 study in the European Respiratory Journal found that asthma patients using Dupixent had a 4.5-fold increased risk of T-cell lymphomas. This is critical evidence because it suggests the cancer risk is caused by the drug itself, not the skin condition. FDA safety data shows that reports of CTCL are 30 times more common in Dupixent patients compared to other medications. Consequently, the FDA has placed Dupixent on its list of medications with Potential Signals of Serious Risks and is formally evaluating the need for regulatory action.
October 2025 Wrongful Death Case
A wrongful death lawsuit filed in Tennessee in October 2025 highlights the tragic stakes. The lawsuit was filed by the daughter of a woman prescribed Dupixent in mid-2024. After just two months of injections, the patient was diagnosed with aggressive Peripheral T-cell Lymphoma and passed away shortly after. The lawsuit alleges Dupixent caused or accelerated her cancer and that the manufacturers failed to warn her doctors about this risk.
Legal Claims Against Manufacturers
We are pursuing claims against Sanofi and Regeneron based on their failure to warn patients and physicians about the risk of T-cell lymphoma. The U.S. label for Dupixent does not mention T-cell lymphoma, depriving doctors and patients of critical safety information needed to make informed treatment decisions.
The companies also failed to instruct physicians to rule out lymphoma before prescribing the drug, even in patients with unusual symptoms or adult-onset presentations that could indicate undiagnosed CTCL rather than simple eczema. The lawsuits further allege negligent misrepresentation, as the companies marketed the drug with slogans like “heal your skin from within” while allegedly concealing evidence that it could fuel cancer growth.
California Legal Advantages
California law offers unique protections for patients harmed by pharmaceutical products. Under the learned intermediary doctrine, drug companies must warn doctors about all known risks. If they fail to do so, they can be held strictly liable for the patient’s injuries.
California courts hold that pharmaceutical companies are experts on their own products and are in the best position to understand emerging risks. When they fail to share what they know about serious safety concerns like the Dupixent-lymphoma link, our laws provide a powerful path to hold them accountable.
Potential Compensation
Individuals diagnosed with T-cell lymphoma after using Dupixent may be entitled to compensation for past and future medical expenses, pain and suffering, and emotional distress. The severity of your injury and the extent of treatment required will significantly impact the value of your claim.
In wrongful death cases, surviving family members may recover damages for loss of companionship and funeral expenses.
Case Eligibility
You may be eligible for a lawsuit if you or a loved one:
- Used Dupixent injections for any approved condition
- Were subsequently diagnosed with Cutaneous T-cell Lymphoma (CTCL), Peripheral T-cell Lymphoma (PTCL), Mycosis Fungoides, or Sézary Syndrome
- Did not have a diagnosis of lymphoma or leukemia before starting Dupixent
Free Case Evaluation
If you were diagnosed with lymphoma after taking Dupixent, our California attorneys will review your case for free. We work on a contingency fee basis, meaning you pay no legal fees unless we win compensation for you.
Time is limited. California’s statute of limitations restricts how long you have to file a claim. Contact us today for a confidential review of your medical records.
GET A FREE CASE EVALUATIONImportant: Always consult your healthcare provider before making any changes to your medications.